AP NEWS

Limb Girdle Muscular Dystrophy (LGMD): Market Insights, Epidemiology and Market Forecast to 2027 - ResearchAndMarkets.com

November 30, 2018

DUBLIN--(BUSINESS WIRE)--Nov 30, 2018--The “Limb Girdle Muscular Dystrophy (LGMD)-Market Insights, Epidemiology and Market Forecast-2027” report has been added to ResearchAndMarkets.com’s offering.

This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Limb Girdle Muscular Dystrophy (LGMD) in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Limb Girdle Muscular Dystrophy (LGMD) from 2016 to 2027 segmented by seven major markets.

The report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Disease Understanding & Treatment Algorithm

An ENMC Consensus in 2017, classified Limb Girdle Muscular Dystrophy (LGMD) based on its inheritance pattern and clinical characteristics into two types: autosomal dominant (LGMD type 1), autosomal recessive (LGMD type 2).

Dominant forms of LGMD have usually a slow course, while recessive form can have an early onset and fast progression, but a number of LGMD2 patients with adult-onset remain ambulant until late in life. The dominant forms are mostly associated with cardiac complications and breathing problems along with muscle wasting.

The report gives the thorough understanding of the LGMD by including details such as disease definition, symptoms, classification, causes, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Limb Girdle Muscular Dystrophy (LGMD) in the US, Europe, and Japan.

Epidemiology

As per Corrado Angelini et. Al. the prevalence of all Limb-Girdle Muscular Dystrophy (LGMDs) types ranges from 4-7 per 100,000, depending on the geographical and ethnic origin.

Large studies have found that in the specific areas i.e. south Europe, calpainopathy is the most prevalent form, while in Northern Europe calpainopathy can be unfrequent; but LGMD 2I is common. A large proportion of recessive LGMD cases is due to dysferlinopathy, sarcoglycanopathies.

According to National Organization for Rare Disorders, LGMD affects males and females in equal numbers. The prevalence of LGMD is unknown, but estimates range from one in 14,500 to one in 123,000. The age of onset can vary greatly even among individuals of the same family. The relative frequencies of the different types of LGMD vary from population to population.

Drug Chapters

At present, there is no cure and no FDA approved therapies for the treatment of Limb-Girdle Muscular Dystrophy (LGMD), current research is mostly focused on the use of novel gene therapies in order to treat the underlying genetic changes.

Major pharmaceutical companies, such as Myonexus Therapeutics (MYO-101, MYO-102) and aTyr Pharma (ATYR1940), etc. are involved in the development of novel therapies for the treatment of Limb Girdle Muscular Dystrophy (LGMD).

Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Companies Featured

Myonexus Therapeutics aTyr Pharma

Key Topics Covered

1. Report Introduction

2. Limb-Girdle Muscular Dystrophy (LGMD) Market Overview at a Glance

3. Disease Background and Overview: Limb-Girdle Muscular Dystrophy (LGMD)

4. Assumptions and Caveats

5. Treatment Practices

6. Key Emerging Therapies

7. Limb-Girdle Muscular Dystrophy (LGMD) Market Size

8. Market Drivers

9. Market Barriers

10. Report Methodology

11. Capabilities

For more information about this report visit https://www.researchandmarkets.com/research/v8cfg8/limb_girdle?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005259/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Musculoskeletal Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/30/2018 09:30 AM/DISC: 11/30/2018 09:30 AM

http://www.businesswire.com/news/home/20181130005259/en

AP RADIO
Update hourly